Cognition, brain atrophy, and cerebrospinal fluid biomarkers changes from preclinical to dementia stage of alzheimer's disease and the influence of apolipoprotein E

Journal of Alzheimer's Disease

Volumn 45, Issue 1, 2015, Pages 253-268

  Susanto, Thomas Adi Kurnia ^a   Pua, Emmanuel Peng Kiat ^a   Zhou, Juan ^a  

^a DUKE NUS MEDICAL SCHOOL   (Singapore)

Author keywords

Alzheimer's disease; amyloid deposition; APOE genotype; magnetic resonance imaging; mild cognitive impairment; preclinical

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; APOLIPOPROTEIN E4; AMYLOID BETA-PROTEIN (1-42); BIOLOGICAL MARKER; PEPTIDE FRAGMENT;

AGED; ALZHEIMER DISEASE; ARTICLE; ATTENTION; BRAIN ATROPHY; BRAIN SIZE; CEREBROSPINAL FLUID; CINGULATE GYRUS; COGNITION; COHORT ANALYSIS; DEMENTIA; DEPTH PERCEPTION; DISEASE COURSE; EXECUTIVE FUNCTION; FEMALE; GENOTYPE; GRAY MATTER; HUMAN; LANGUAGE; MAJOR CLINICAL STUDY; MALE; MEMORY; MEMORY DISORDER; MILD COGNITIVE IMPAIRMENT; PARIETAL GYRUS; PRIORITY JOURNAL; TEMPORAL LOBE; THALAMUS; VERY ELDERLY; VOXEL BASED MORPHOMETRY; ANALYSIS OF VARIANCE; ATROPHY; BRAIN; COGNITION DISORDERS; COMPLICATION; GENETICS; IMAGE PROCESSING; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PSYCHOLOGICAL RATING SCALE;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANALYSIS OF VARIANCE; APOLIPOPROTEINS E; ATROPHY; BIOMARKERS; BRAIN; COGNITION DISORDERS; COHORT STUDIES; DEMENTIA; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; NEUROPSYCHOLOGICAL TESTS; PEPTIDE FRAGMENTS; PSYCHIATRIC STATUS RATING SCALES;

EID: 84924115342     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-142451     Document Type: Article

References (54)

1. Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, Delacourte A, Galasko D, Gauthier S, Jicha G, Meguro K, O'Brien J, Pasquier F, Robert P, Rossor M, Salloway S, Stern Y, Visser PJ, Scheltens P (2007) Research criteria for the diagnosis of Alzheimer's disease: Revising the NINCDS-ADRDA criteria. Lancet Neurol 6, 734-746.
2. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR, Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern Y, Yaffe K, Carrillo MC, Thies B, Morrison-Bogorad M, Wagster MV, Phelps CH (2011) Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7, 280-292.
3. Price JL, Morris JC (1999) Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann Neurol 45, 358-368.
4. Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, Szoeke C, Macaulay SL, Martins R, Maruff P, Ames D, Rowe CC, Masters CL (2013) Amyloid aβ deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: A prospective cohort study. Lancet Neurol 12, 357-367.
5. Mullard A (2012) Sting of Alzheimer's failures offset by upcoming prevention trials. Nat Rev Drug Discov 11, 657-660.
6. Twamley EW, Legendre Ropacki SA, Bondi MW (2006) Neuropsychological and neuroimaging changes in preclinical Alzheimer's disease. J Int Neuropsychol Soc 12, 707-735.
7. Chen P, Ratcliff G, Belle SH, Cauley JA, DeKosky ST, GanguliM (2001) Patterns of cognitive decline in presymptomatic Alzheimer disease:Aprospective community study. Arch Gen Psychiatry 58, 853-858.
8. Hulette CM, Welsh-Bohmer KA, Murray MG, Saunders AM, Mash DC, McIntyre LM (1998) Neuropathological and neuropsychological changes in "normal" aging: Evidence for preclinical Alzheimer disease in cognitively normal individuals. J Neuropathol Exp Neurol 57, 1168-1174.
9. Rapp MA, Reischies FM (2005) Attention and executive control predict Alzheimer disease in late life: Results from the Berlin Aging Study (BASE). Am J Geriatr Psychiatry 13, 134-141.
10. Ellis KA, Lim YY, Harrington K, Ames D, Bush AI, Darby D, Martins RN, Masters CL, Rowe CC, Savage G, Szoeke C, Villemagne VL, Maruff P (2013) Decline in cognitive function over 18 months in healthy older adults with high amyloid-beta. J Alzheimers Dis 34, 861-871.
11. Goldman WP, Price JL, Storandt M, Grant EA, McKeel DW Jr., Rubin EH, Morris JC (2001) Absence of cognitive impairment or decline in preclinical Alzheimer's disease. Neurology 56, 361-367.
12. Beach TG, Monsell SE, Phillips LE, KukullW (2012) Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010. J Neuropathol Exp Neurol 71, 266-273.
13. Bunce D, Fratiglioni L, Small BJ, Winblad B, Backman L (2004) APOE and cognitive decline in preclinical Alzheimer disease and non-demented aging. Neurology 63, 816-821.
14. Laukka EJ, Jones S, Small BJ, Fratiglioni L, Backman L (2004) Similar patterns of cognitive deficits in the preclinical phases of vascular dementia and Alzheimer's disease. J Int Neuropsychol Soc 10, 382-391.
15. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, SmallGW, Roses AD, Haines JL, Pericak-Vance MA (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261, 921-923.
16. Geroldi C, Pihlajamaki M, Laakso MP, DeCarli C, Beltramello A, Bianchetti A, Soininen H, Trabucchi M, Frisoni GB (1999) APOE-epsilon4 is associated with less frontal and more medial temporal lobe atrophy in AD. Neurology 53, 1825-1832.
17. Lehtovirta M, Laakso MP, Soininen H, Helisalmi S, Mannermaa A, Helkala EL, Partanen K, Ryynanen M, Vainio P, Hartikainen P, Riekkinen PJ Sr (1995) Volumes of hippocampus, amygdala and frontal lobe in Alzheimer patients with different apolipoprotein E genotypes. Neuroscience 67, 65-72.
18. Mori E, Lee K, Yasuda M, Hashimoto M, Kazui H, Hirono N, Matsui M (2002) Accelerated hippocampal atrophy in Alzheimer's disease with apolipoprotein E epsilon4 allele. Ann Neurol 51, 209-214.
19. Lehtovirta M, Soininen H, Helisalmi S, Mannermaa A, Helkala EL, Hartikainen P, Hanninen T, Ryynanen M, Riekkinen PJ (1996) Clinical and neuropsychological characteristics in familial and sporadic Alzheimer's disease: Relation to apolipoprotein E polymorphism. Neurology 46, 413-419.
20. Van Der Vlies AE, Pijnenburg YA, Koene T, Klein M, Kok A, Scheltens P, Van Der FlierWM (2007) Cognitive impairment in Alzheimer's disease is modified by APOE genotype. Dement Geriatr Cogn Disord 24, 98-103.
21. Wolk DA, Dickerson BC (2010) Apolipoprotein E (APOE) genotype has dissociable effects on memory and attentionalexecutive network function in Alzheimer's disease. Proc Natl Acad Sci U S A 107, 10256-10261.
22. Drzezga A, Grimmer T, Henriksen G, Muhlau M, Perneczky R, Miederer I, Praus C, Sorg C, Wohlschlager A, Riemenschneider M, Wester HJ, Foerstl H, Schwaiger M, Kurz A (2009) Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease. Neurology 72, 1487-1494.
23. Agosta F, Vossel KA, Miller BL, Migliaccio R, Bonasera SJ, Filippi M, Boxer AL, Karydas A, Possin KL, Gorno-Tempini ML (2009) Apolipoprotein E epsilon4 is associated with disease-specific effects on brain atrophy in Alzheimer's disease and frontotemporal dementia. Proc Natl Acad Sci U S A 106, 2018-2022.
24. De Meyer G, Shapiro F, Vanderstichele H, Vanmechelen E, Engelborghs S, De Deyn PP, Coart E, Hansson O, Minthon L, Zetterberg H, Blennow K, Shaw L, Trojanowski JQ (2010) Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. Arch Neurol 67, 949-956.
25. Palmqvist S, Zetterberg H, Blennow K, Vestberg S, Andreasson U, Brooks DJ, Owenius R, Hagerstrom D, Wollmer P, Minthon L, Hansson O (2014) Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid betaamyloid 42:Across-validation study against amyloid positron emission tomography. JAMA Neurol 71, 1282-1289.
26. Zhou J, Gennatas ED, Kramer JH, Miller BL, Seeley WW (2012) Predicting regional neurodegeneration from the healthy brain functional connectome. Neuron 73, 1216-1227.
27. ADNI, Study Documents, Alzheimer's Disease Neuroimaging Initiative, http://adni.loni.usc.edu/methods/documents/, Accessed 9 July 2013.
28. Petersen RC, Aisen PS, Beckett LA, Donohue MC, Gamst AC, Harvey DJ, Jack CR, Jagust WJ, Shaw LM, Toga AW, Trojanowski JQ, Weiner MW (2010) Alzheimer's Disease Neuroimaging Initiative (ADNI): Clinical characterization. Neurology 74, 201-209.
29. Gomar JJ, Bobes-Bascaran MT, Conejero-Goldberg C, Davies P, Goldberg TE (2011) Utility of combinations of biomarkers, cognitive markers, and risk factors to predict conversion from mild cognitive impairment to Alzheimer disease in patients in the Alzheimer's disease neuroimaging initiative. Arch Gen Psychiatry 68, 961-969.
30. Park LQ, Gross AL, McLaren DG, Pa J, Johnson JK, Mitchell M, Manly JJ (2012) Confirmatory factor analysis of the ADNI Neuropsychological Battery. Brain Imaging Behav 6, 528-539.
31. Zhou J, Greicius MD, Gennatas ED, Growdon ME, Jang JY, Rabinovici GD, Kramer JH, Weiner M, Miller BL, Seeley WW (2010) Divergent network connectivity changes in behavioural variant frontotemporal dementia and Alzheimer's disease. Brain 133, 1352-1367.
32. Bjerke M, Portelius E, Minthon L, Wallin A, Anckarsater H, Anckarsater R, Andreasen N, Zetterberg H, Andreasson U, Blennow K (2010) Confounding factors influencing amyloid Beta concentration in cerebrospinal fluid. Int J Alzheimers Dis (2010), pii: 986310.
33. Buchhave P, Minthon L, Zetterberg H, Wallin AK, Blennow K, Hansson O (2012) Cerebrospinal fluid levels of betaamyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry 69, 98-106.
34. Backman L, Jones S, Berger AK, Laukka EJ, Small BJ (2004) Multiple cognitive deficits during the transition to Alzheimer's disease. J Intern Med 256, 195-204.
35. Johnson DK, Storandt M, Morris JC, Galvin JE (2009) Longitudinal study of the transition from healthy aging to alzheimer disease. Arch Neurol 66, 1254.
36. Buckner RL, Sepulcre J, Talukdar T, Krienen FM, Liu H, Hedden T, Andrews-Hanna JR, Sperling RA, Johnson KA (2009) Cortical hubs revealed by intrinsic functional connectivity: Mapping, assessment of stability, and relation to Alzheimer's disease. J Neurosci 29, 1860-1873.
37. Braak H, Braak E, Bohl J (1993) Staging of Alzheimer-related cortical destruction. Eur Neurol 33, 403-408.
38. Ono K, Condron MM, Teplow DB (2009) Structureneurotoxicity relationships of amyloid beta-protein oligomers. Proc Natl Acad Sci U S A 106, 14745-14750.
39. Sheline YI, Raichle ME, Snyder AZ, Morris JC, Head D, Wang S, Mintun MA (2010) Amyloid plaques disrupt resting state default mode network connectivity in cognitively normal elderly. Biol Psychiatry 67, 584-587.
40. Nelson PT, Alafuzoff I, Bigio EH, Bouras C, Braak H, Cairns NJ, Castellani RJ, Crain BJ, Davies P, Del Tredici K, Duyckaerts C, Frosch MP, Haroutunian V, Hof PR, Hulette CM, Hyman BT, Iwatsubo T, Jellinger KA, Jicha GA, Kovari E, KukullWA, Leverenz JB, Love S, Mackenzie IR, Mann DM, Masliah E, McKee AC, Montine TJ, Morris JC, Schneider JA, Sonnen JA, Thal DR, Trojanowski JQ, Troncoso JC, Wisniewski T, Woltjer RL, Beach TG (2012) Correlation of Alzheimer disease neuropathologic changes with cognitive status: A review of the literature. J Neuropathol Exp Neurol 71, 362-381.
41. Mattsson N, Insel PS, Nosheny R, Tosun D, Trojanowski JQ, Shaw LM, Jack CR Jr, Donohue MC, Weiner MW (2014) Emerging beta-amyloid pathology and accelerated cortical atrophy. JAMA Neurol 71, 725-734.
42. Mahley RW, Rall SC Jr (2000) Apolipoprotein E: Far more than a lipid transport protein. Annu Rev Genomics Hum Genet 1, 507-537.
43. Raber J, Huang Y, Ashford JW (2004) ApoE genotype accounts for the vast majority of AD risk and AD pathology. Neurobiol Aging 25, 641-650.
44. Soininen HS, Riekkinen PJ Sr (1996) Apolipoprotein E, memory and Alzheimer's disease. Trends Neurosci 19, 224-228.
45. Krzywkowski P, Ghribi O, Gagne J, Chabot C, Kar S, Rochford J, Massicotte G, Poirier J (1999) Cholinergic systems and long-term potentiation in memory-impaired apolipoprotein. Neuroscience 92, 1273-1286.
46. Poirier J, Delisle MC, Quirion R, Aubert I, Farlow M, Lahiri D, Hui S, Bertrand P, Nalbantoglu J, Gilfix BM, Gauthier S (1995) Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment. Proc Natl Acad Sci U S A 92, 12260-12264.
47. Hashimoto M, Yasuda M, Tanimukai S, Matsui M, Hirono N, Kazui H, Mori E (2001) Apolipoprotein E β4 and the pattern of regional brain atrophy in Alzheimer's disease. Neurology 57, 1461-1466.
48. Smith GE, Bohac DL, Waring SC, Kokmen E, Tangalos EG, Ivnik RJ, Petersen RC (1998) Apolipoprotein E genotype influences cognitive phenotype' in patients with Alzheimer's disease but not in healthy control subjects. Neurology 50, 355-362.
49. Ossenkoppele R, Van Der Flier WM, Zwan MD, Adriaanse SF, Boellaard R, Windhorst AD, Barkhof F, Lammertsma AA, Scheltens P, Van Berckel BN (2013) Differential effect of APOE genotype on amyloid load and glucose metabolism in AD dementia. Neurology 80, 359-365.
50. Machulda MM, Jones DT, Vemuri P, McDade E, Avula R, Przybelski S, Boeve BF, Knopman DS, Petersen RC, Jack CR Jr (2011) Effect of APOE epsilon4 status on intrinsic network connectivity in cognitively normal elderly subjects. Arch Neurol 68, 1131-1136.
51. Fox MD, Snyder AZ, Vincent JL, Corbetta M, Van Essen DC, RaichleME (2005) The human brain is intrinsically organized into dynamic, anticorrelated functional networks. Proc Natl Acad Sci U S A 102, 9673-9678.
52. Seeley WW (2011) Divergent network connectivity changes in healthy APOE epsilon4 carriers: Disinhibition or compensation? Arch Neurol 68, 1107-1108.
53. Zhou J, Seeley WW (2014) Network dysfunction in Alzheimer's disease and frontotemporal dementia: Implications for psychiatry. Biol Psychiatry 75, 565-573.
54. Menon V, Uddin LQ (2010) Saliency, switching, attention and control: A network model of insula function. Brain Struct Funct 214, 655-667.